Minerva Neurosciences (NERV) Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant vs Quetiapine as Adjunctive Therapy to Antidepressants in Patients With MDD
Tweet Send to a Friend
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
